Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;80(18):1973-1980.
doi: 10.1007/s40265-020-01433-6.

Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia

Affiliations
Review

Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia

Hannah A Blair. Drugs. 2020 Dec.

Abstract

Venetoclax (Venclexta®; Venclyxto®) is a first-in-class, oral, selective inhibitor of B cell lymphoma 2 (BCL2). In several countries, including the USA and those of the EU, venetoclax is indicated in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Approval was based on the results of the phase III CLL14 trial in patients with previously untreated CLL and co-existing conditions. In this study, fixed-duration (12 months) targeted treatment with venetoclax + obinutuzumab resulted in significantly longer progression-free survival (PFS; primary endpoint) relative to fixed-duration chemoimmunotherapy with chlorambucil + obinutuzumab. Venetoclax + obinutuzumab was also associated with significantly higher rates of undetectable minimal residual disease (MRD), complete response and overall response than chlorambucil + obinutuzumab. Improvements in clinical outcomes with venetoclax + obinutuzumab were maintained during long-term follow-up, when all patients had been off treatment for ≥ 2 years. No significant between-group difference was observed in overall survival (OS). Venetoclax had an acceptable tolerability profile. Notable adverse events such as grade 3 or 4 neutropenia can be managed with supportive therapy and venetoclax dose modifications. In conclusion, fixed-duration venetoclax + obinutuzumab represents an important chemotherapy-free first-line treatment option for patients with CLL, particularly those who are not fit enough to receive intensive chemoimmunotherapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Sengar M, Jain H, Rajendra A, et al. Frontline therapy of chronic lymphocytic leukemia: changing treatment paradigm. Curr Hematol Malig Rep. 2020;15(3):168–76. - DOI
    1. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2020. https://doi.org/10.1016/j.annonc.2020.09.019 . - DOI - PubMed
    1. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–87. - DOI
    1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): chronic lymphocytic leukaemia/small lymphocytic lymphoma. Version 1.2021. 2020. https://www.nccn.org . Accessed 19 Oct 2020.
    1. Von Tresckow J, Eichhorst B, Bahlo J, et al. The treatment of chronic lymphatic leukemia. Dtsch Arzebl Int. 2019;116(4):41–6.

MeSH terms

LinkOut - more resources